<HashMap><database>GEO</database><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310378</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Engineered Vesicular Stomatitis Virus for Cancer-Specific Delivery of Potent Immunotherapy Payloads</name><description>The lack of tumor-specific targeting by oncolytic viruses (OVs) restricts their therapeutic potential. Here, we report a “cap-linker” strategy to modify the vesicular stomatitis virus (VSV) glycoprotein (G protein, VSV-GIN). The modified VSV (Pro-VSVIN) loses its ability to infect cells until present in the tumor microenvironment, where the linker is cleaved by tumor-enriched matrix metalloproteases (MMPs). When Pro-VSVIN is armed with a single-chain IL-12 (Pro-VSVIN-IL-12) and systemically injected into MC38 tumor-bearing mice, Pro-VSVIN-IL-12 shows a markedly improved safety profile and eradicates tumors. The efficacy of Pro-VSVIN-IL-12 was further improved when combined with PD-1 checkpoint blockade. Compared to WT VSVIN that carries IL-12, intravenously injected Pro-VSVIN-IL-12 leads to strong Th1 immunity, near abolishment of regulatory T cells, and CD8+ T cell activation in tumors. This preclinical work demonstrates a new tumor-specific targeting strategy of VSV for enhanced immunotherapy safety with superior efficacy.</description><dates><publication>2026/05/30</publication></dates><accession>GSE310378</accession><cross_references><GSM>GSM9294937</GSM><GSM>GSM9294935</GSM><GSM>GSM9294936</GSM><GSM>GSM9294933</GSM><GSM>GSM9294934</GSM><GPL>34290</GPL><GSE>310378</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>